Navigation Links
Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
Date:3/16/2009

rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the return of development and commercialization rights to blinatumomab, the future development of blinatumomab and a new BiTE antibody binding to CD19,
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... With its ... sacrifice selectivity to achieve faster flow rates in comparison to nylon or polyethersulfone ... open space to allow easy liquid flow while trapping particulates as small as ...
(Date:6/30/2015)... 2015  The University of California, San Diego,s ... UC San Diego Extension announced their third annual ...  12 – 14, 2015, at UC San Diego ... an intense exposure to best practices and the ... to biologists, process engineers and business executives planning ...
(Date:6/30/2015)... Edwardsville, IL (PRWEB) , ... June 30, 2015 ... ... resigned effective August 14. She has accepted the position of vice president of ... on August 17. , “I greatly appreciated the opportunity to lead SIUE ...
(Date:6/29/2015)... , June 30, 2015   Pharnext SAS today ... developed for the treatment of Charcot-Marie-Tooth Type 1A (CMT1A), is ... the 2015 Peripheral Nerve Society (PNS) Biennial Meeting at the ... , June 27 - July 2, 2015. At ... Wed July 1, 5p.m. to 7p.m. EDT: ...
Breaking Biology Technology:New Nanofiber Membrane Provides Fast, Efficient Filtration 2UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2
... International, Inc.,(Quest) announced they will show true 12-bit, ... and the Totoku, ME551i2,medical LCD display, at the ... be held in Seattle, Washington., Quest will ... Pro 8-Core workstation with two ME551i2 medical, LCD ...
... Call Scheduled Friday, April 4, 2008 at 8:30 a.m. EDT - ... Recent Highlights:, - 2007 pro forma consolidated net sales increased 21.2% year-over-year to ... $317.2 million, - Provided 2008 guidance: revenue ... of $28 million to $30 million, - ...
... 3, 2008 Spherix,Incorporated (Nasdaq: SPEX ) reported ... 31, 2007. The Company,s research and development costs,jumped to ... the launch of,the Company,s Phase 3 clinical trial for ... 2007. The trial is expected to last at least ...
Cached Biology Technology:Quest International Announces They Will be First in US to Exhibit True 12-Bit Grayscale Mammographic Images 2Chem Rx Corporation Reports Full Year 2007 Financial Results 2Chem Rx Corporation Reports Full Year 2007 Financial Results 3Chem Rx Corporation Reports Full Year 2007 Financial Results 4Chem Rx Corporation Reports Full Year 2007 Financial Results 5Chem Rx Corporation Reports Full Year 2007 Financial Results 6Chem Rx Corporation Reports Full Year 2007 Financial Results 7Chem Rx Corporation Reports Full Year 2007 Financial Results 8Chem Rx Corporation Reports Full Year 2007 Financial Results 9Chem Rx Corporation Reports Full Year 2007 Financial Results 10Chem Rx Corporation Reports Full Year 2007 Financial Results 11Chem Rx Corporation Reports Full Year 2007 Financial Results 12Chem Rx Corporation Reports Full Year 2007 Financial Results 13Chem Rx Corporation Reports Full Year 2007 Financial Results 14Chem Rx Corporation Reports Full Year 2007 Financial Results 15Spherix Reports 2007 Financial Results 2
(Date:6/17/2015)... Germany , June 17, 2015 ... today launched new Investigator ® STR assay kits for ... the United States . The new genetic fingerprint kits ... markers (short tandem repeats or STRs) for DNA matching. They ... quality of DNA in each sample, a novel QIAGEN technology ...
(Date:6/16/2015)... 16, 2015 /CNW Telbec/ - handyem Inc. and ... the incorporation of handyem,s HPC-150 portable flow cytometer ... Mo-POD™. This unprecedented model of mobile laboratory platform ... the Pennsylvania Convention Center, ... th to 18 th 2015.  By ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... communicated that it will amount to at least 340 MSEK ... to the rapid increase in market growth and orders received ... communicated guidance that revenue for 2015 will exceed 1,500 MSEK ... to approximately 2,200 MSEK. Due to receipt of ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... change the world has seen in the last 100,000 years ... interglacial period. New research from the Niels Bohr Institute at ... the rise in temperature and the rise in the atmospheric ... time. The results have been published in the scientific journal, ...
... new study finds that mice have a distinct neural ... is associated with instinctually important smells such as those ... in Proceedings of the National Academy of Sciences ... have specially hardwired neural circuitry to trigger instinctive behavior ...
... breeders announced a new high-yielding variety of oats. ... height, withstands falling over (lodging), matures earlier and produces ... seed yield potential, exceeding the Rodgers variety by 20 ... 32.2-pound bushel compared to 31.9-pound bushel for Rodgers," said ...
Cached Biology News:Rise in temperatures and CO2 follow each other closely in climate change 2Rise in temperatures and CO2 follow each other closely in climate change 3Mice have distinct subsystem to handle smell associated with fear 2Mice have distinct subsystem to handle smell associated with fear 3Clemson plant breeders roll out new oat variety 2
Proliferin (N-14)...
Porcine Aortic Smooth Muscle Cells (PAOSMC) (>500,000 cells)...
... The Finnpipette BioControl is a major ... A complete liquid handling system - ... interchangeable tip cone modules. All five ... cone modules fit one handle. The ...
Bovine Pulmonary Artery Smooth Muscle Cells (BPASMC) (>500,000 cells)...
Biology Products: